Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1244-2


The changes in pathways of clot formation and lysis, and their interactions with cells and tissues that precede or accompany cancer.


Blood coagulation dyscrasias have been linked to cancer for centuries. Tumor regression with leeching and bleeding and thrombosis complicating malignancy were among the early cues to an elegant but ruinous cybernetics. In 1867, Trousseau described “painful edema” (deep vein thrombosis, DVT) with both established and as yet undiscovered malignancies. The common occurrence of venous thromboembolism (VTE) with cancer signals poor survival and is a common cause of death in cancer patients. Compression of veins and organ damage by tumor masses, superimposed infection, surgery, radiation therapy, chemotherapy, hormonal therapy, growth factor/cytokine administration, and antiangiogenic therapy predispose to cancer-related thrombosis. Cancer-related thrombotic syndromes besides VTE include nonbacterial thrombotic (marantic; pertaining...


Coagulation Activation Coagulation Pathway Coagulation Mechanism Occult Malignancy Epsilon Aminocaproic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access


  1. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266–1271CrossRefPubMedGoogle Scholar
  2. Dvorak HF, Rickles FR (2006) Malignancy and hemostasis. In: Colman RW, Marder VJ, George JN, Goldhaber SZ (eds) Hemostasis and thrombosis, basic principles and clinical practice, 5th edn. Lipincott, Williams & Wilkins, Philadelphia, pp 851–873Google Scholar
  3. Levine MN, Lee AYY, Kakkar AK (2006) Cancer and thrombosis. In: Colman RW, Marder VJ, George JN, Goldhaber SZ (eds) Hemostasis and thrombosis, basic principles and clinical practice, 5th edn. Lipincott, Williams & Wilkins, Philadelphia, pp 1251–1262Google Scholar
  4. Miller GJ, Bauer KA, Howarth DJ et al (2004) Increased incidence of neoplasia of the digestive track in men with persistent activation of the coagulation pathway. J Thromb Haemost 2:2107–2114CrossRefPubMedGoogle Scholar
  5. Norman PH, Thall PF, Purugganan RV, Riedel BJ, Thakar DR, Rice DC, Huynh L, Qiao W, Wen S, Smythe WR (2009) A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 115:833–841CrossRefPubMedGoogle Scholar
  6. Pan CW, Shen ZJ, Ding GQ (2008) The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. J Urol 179:1307–1311CrossRefPubMedGoogle Scholar
  7. Rossi C, Hess S, Eckl RW, di Lena A, Bruno A, Thomas O, Poggi A (2006) Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice. J Thromb Haemost 4:608–613CrossRefPubMedGoogle Scholar
  8. Zacharski LR (2002) Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett 186:1–9CrossRefPubMedGoogle Scholar
  9. Zacharski LR (2003) Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer. Semin Thromb Hemost 29:239–246CrossRefPubMedGoogle Scholar
  10. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW (2008) Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100:996–1002CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.VA HospitalWhite River JunctionUSA
  2. 2.Lahey Center for Hematology/Oncology at Parkland Medical CenterSalemUSA